David A. Six, Ph.D. is a Principal Scientist II at Venatorx Pharmaceuticals, where he supports the clinical-stage cefepime-taniborbactam and ceftibuten-ledaborbactam etzadroxil combination and novel non-β-lactam inhibitors of penicillin-binding proteins. David also works closely with external collaborators, including Professor Robert Bonomo, MD (Case Western).

Before joining Venatorx in 2018, David spent more than 8 years at Novartis, where he led antibacterial drug discovery programs and developed assays to measure bacterial compound accumulation. As part of this, he also led a team that developed a solid-phase extraction mass spectrometry assay to increase the efficiency of assays to measure bacterial compound accumulation. David has authored over 40 peer-reviewed publications and also owns a patent.

David received his masters and doctorate degree from the University of California, San Diego, USA and did postdoctoral work at Duke University Medical Center with Professor Christan R.H. Raetz, MD/PhD.